Methamphetamine: Effects on the brain, gut and immune system

Pharmacological Research

Volumn 120, Issue , 2017, Pages 60-67

  Prakash, Monica D ^a   Tangalakis, Kathy ^a   Antonipillai, Juliana ^a   Stojanovska, Lily ^a   Nurgali, Kulmira ^a   Apostolopoulos, Vasso ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Anxiety; Depression; Gastrointestinal system; Ice; Immune system; Methamphetamine; Nervous system

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METHAMPHETAMINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; CENTRAL STIMULANT AGENT;

ADRENERGIC SYSTEM; BLOOD BRAIN BARRIER; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; GENE CONTROL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NEUROPATHOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CHEMICALLY INDUCED; DELUSION; DEPRESSION; DRUG EFFECTS; GASTROINTESTINAL TRACT; PSYCHOSIS;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DELUSIONS; DEPRESSION; GASTROINTESTINAL TRACT; HUMANS; IMMUNE SYSTEM; METHAMPHETAMINE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 85016303924     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.03.009     Document Type: Review

References (114)

1. [1] Hauer, P., Systemic affects of methamphetamine use. S. D. Med. 63:8 (2010), 285–287.
2. [2] Rommel, N., Rohleder, N.H., Wagenpfeil, S., Haertel-Petri, R., Kesting, M.R., Evaluation of methamphetamine-associated socioeconomic status and addictive behaviors, and their impact on oral health. Addict. Behav. 50 (2015), 182–187.
3. [3] Salamanca, S.A., Sorrentino, E.E., Nosanchuk, J.D., Martinez, L.R., Impact of methamphetamine on infection and immunity. Front. Neurosci., 8, 2014, 445.
4. [4] Defalque, R.J., Wright, A.J., Methamphetamine for Hitler's Germany: 1937–1945. Bull. Anesth. Hist. 29:2 (2011), 21–24 32.
5. [5] Cartier, J., Farabee, D., Prendergast, M.L., Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J. Interpers. Violence 21:4 (2006), 435–445.
6. [6] McGuinness, T., Methamphetamine abuse. Am. J. Nurs. 106:12 (2006), 54–59.
7. [7] Rutkowski, B.A., California substance abuse research consortium, September 2005: update on recent methamphetamine trends in four California regions. J. Psychoact. Drugs(Suppl. 3), 2006, 369–375.
8. [8] Roche, A., McEntee, A., Fischer, J., Kostadinov, V., Methamphetamine use in Australia. National Centre for Education and Training on Addiction (NCETA), 2015, Flinders University.
9. [9] Kirkpatrick, M.G., Haney, M., Vosburg, S.K., Comer, S.D., Foltin, R.W., Hart, C.L., Methamphetamine self-administration by humans subjected to abrupt shift and sleep schedule changes. Psychopharmacology (Berl.) 203:4 (2009), 771–780.
10. [10] Mendelson, J., Rawson, R., Newton, T., Galloway, G., de Wit, H., Dewey, S.L., Hart, C.L., Epstein, D.H., Treatment of methamphetamine dependence. Mayo Clin. Proc. 83:3 (2008), 369–370 author reply 370-361.
11. [11] Perez, A.Y., Kirkpatrick, M.G., Gunderson, E.W., Marrone, G., Silver, R., Foltin, R.W., Hart, C.L., Residual effects of intranasal methamphetamine on sleep, mood, and performance. Drug Alcohol Depend. 94:1–3 (2008), 258–262.
12. [12] Padilla, R., Ritter, A.V., Meth mouth: methamphetamine and oral health. J. Esthet. Restor. Dent. 20:2 (2008), 148–149.
13. [13] Shaner, J.W., Kimmes, N., Saini, T., Edwards, P., Meth mouth: rampant caries in methamphetamine abusers. Aids Patient Care STDS 20:3 (2006), 146–150.
14. [14] Williams, N., Covington, J.S. 3rd, Methamphetamine and meth mouth: an overview. J Tenn Dent Assoc. 86:4 (2006), 32–35.
15. [15] Ruda-Kucerova, J., Amchova, P., Babinska, Z., Dusek, L., Micale, V., Sulcova, A., Sex differences in the reinstatement of methamphetamine seeking after forced abstinence in sprague-Dawley rats. Front. Psychiatry, 6, 2015, 91.
16. [16] Du, J., Quan, M., Zhuang, W., Zhong, N., Jiang, H., Kennedy, D.N., Harrington, A., Ziedonis, D., Fan, X., Zhao, M., Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. Behav. Brain Res. 289 (2015), 78–83.
17. [17] Hser, Y.I., Evans, E., Huang, Y.C., Treatment outcomes among women and men methamphetamine abusers in California. J. Subst. Abuse Treat. 28:1 (2005), 77–85.
18. [18] Park, M., Kim, H.J., Lim, B., Wylegala, A., Toborek, M., Methamphetamine-induced occludin endocytosis is mediated by the Arp2/3 complex-regulated actin rearrangement. J. Biol. Chem. 288:46 (2013), 33324–33334.
19. [19] Kiyatkin, E.A., Sharma, H.S., Permeability of the blood-brain barrier depends on brain temperature. Neuroscience 161:3 (2009), 926–939.
20. [20] Ji, X., Liu, W., Xie, K., Liu, W., Qu, Y., Chao, X., Chen, T., Zhou, J., Fei, Z., Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress. Brain Res. 1354 (2010), 196–205.
21. [21] Price, T.O., Ercal, N., Nakaoke, R., Banks, W.A., HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res. 1045:1–2 (2005), 57–63.
22. [22] Sharma, H.S., Sharma, A., Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog. Brain Res. 162 (2007), 245–273.
23. [23] Zehendner, C.M., Librizzi, L., Hedrich, J., Bauer, N.M., Angamo, E.A., de Curtis, M., Luhmann, H.J., Moderate hypoxia followed by reoxygenation results in blood-brain barrier breakdown via oxidative stress-dependent tight-junction protein disruption. PLoS One, 8(12), 2013, e82823.
24. [24] Kermode, A.G., Thompson, A.J., Tofts, P., MacManus, D.G., Kendall, B.E., Kingsley, D.P., Moseley, I.F., Rudge, P., McDonald, W.I., Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113:Pt. 5 (1990), 1477–1489.
25. [25] Zhu, R., Yang, T., Kobeissy, F., Mouhieddine, T.H., Raad, M., Nokkari, A., Gold, M.S., Wang, K.K., Mechref, Y., The effect of chronic methamphetamine exposure on the hippocampal and olfactory bulb neuroproteomes of rats. PLoS One, 11(4), 2016, e0151034.
26. [26] Mahajan, S.D., Aalinkeel, R., Sykes, D.E., Reynolds, J.L., Bindukumar, B., Adal, A., Qi, M., Toh, J., Xu, G., Prasad, P.N., Schwartz, S.A., Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 1203 (2008), 133–148.
27. [27] Ramirez, S.H., Potula, R., Fan, S., Eidem, T., Papugani, A., Reichenbach, N., Dykstra, H., Weksler, B.B., Romero, I.A., Couraud, P.O., Persidsky, Y., Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J. Cereb. Blood Flow Metab. 29:12 (2009), 1933–1945.
28. [28] Bemeur, C., Desjardins, P., Butterworth, R.F., Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy. Metab. Brain Dis. 25:1 (2010), 3–9.
29. [29] Rodrigo, R., Erceg, S., Felipo, V., Neurons exposed to ammonia reproduce the differential alteration in nitric oxide modulation of guanylate cyclase in the cerebellum and cortex of patients with liver cirrhosis. Neurobiol. Dis. 19:1–2 (2005), 150–161.
30. [30] Northrop, N.A., Halpin, L.E., Yamamoto, B.K., Peripheral ammonia and blood brain barrier structure and function after methamphetamine. Neuropharmacology 107 (2016), 18–26.
31. [31] Martins, T., Baptista, S., Goncalves, J., Leal, E., Milhazes, N., Borges, F., Ribeiro, C.F., Quintela, O., Lendoiro, E., Lopez-Rivadulla, M., Ambrosio, A.F., Silva, A.P., Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 1411 (2011), 28–40.
32. [32] Parikh, N.U., Aalinkeel, R., Reynolds, J.L., Nair, B.B., Sykes, D.E., Mammen, M.J., Schwartz, S.A., Mahajan, S.D., Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: neuroprotective role in maintaining blood brain barrier integrity. Brain Res. 1624 (2015), 175–187.
33. [33] Rusyniak, D.E., Neurologic manifestations of chronic methamphetamine abuse. Neurol. Clin. 29:3 (2011), 641–655.
34. [34] NIH, DrugFacts: Methamphetamine. 2016, NIH.
35. [35] Metzger, R.R., Haughey, H.M., Wilkins, D.G., Gibb, J.W., Hanson, G.R., Fleckenstein, A.E., Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 295:3 (2000), 1077–1085.
36. [36] Hong, S.J., Zhang, D., Zhang, L.H., Yang, P., Wan, J., Yu, Y., Wang, T.H., Feng, Z.T., Li, L.H., Yew, D.T., Expression of dopamine transporter in the different cerebral regions of methamphetamine-dependent rats. Hum. Exp. Toxicol. 34:7 (2015), 707–717.
37. [37] Yuan, J., Lv, R., Robert Brasic, J., Han, M., Liu, X., Wang, Y., Zhang, G., Liu, C., Li, Y., Deng, Y., Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Res. 221:1 (2014), 92–96.
38. [38] Haughey, H.M., Fleckenstein, A.E., Metzger, R.R., Hanson, G.R., The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J. Neurochem. 75:4 (2000), 1608–1617.
39. [39] Sogawa, C., Sogawa, N., Tagawa, J., Fujino, A., Ohyama, K., Asanuma, M., Funada, M., Kitayama, S., 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol. Lett. 170:1 (2007), 75–82.
40. [40] Cass, W.A., Manning, M.W., Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J. Neurosci. 19:17 (1999), 7653–7660.
41. [41] Allard, P.O., Rinne, J., Marcusson, J.O., Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res. 637:1–2 (1994), 262–266.
42. [42] Morgan, D.G., May, P.C., Finch, C.E., Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J. Am. Geriatr. Soc. 35:4 (1987), 334–345.
43. [43] Murray, A.M., Weihmueller, F.B., Marshall, J.F., Hurtig, H.I., Gottleib, G.L., Joyce, J.N., Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37:3 (1995), 300–312.
44. [44] Lam, V.M., Espinoza, S., Gerasimov, A.S., Gainetdinov, R.R., Salahpour, A., In-vivo pharmacology of trace-amine associated receptor 1. Eur. J. Pharmacol. 763:Pt. B (2015), 136–142.
45. [45] Miller, G.M., The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 116:2 (2011), 164–176.
46. [46] Borowsky, B., Adham, N., Jones, K.A., Raddatz, R., Artymyshyn, R., Ogozalek, K.L., Durkin, M.M., Lakhlani, P.P., Bonini, J.A., Pathirana, S., Boyle, N., Pu, X., Kouranova, E., Lichtblau, H., Ochoa, F.Y., Branchek, T.A., Gerald, C., Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 98:16 (2001), 8966–8971.
47. [47] Miller, G.M., Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1). J. Med. Chem. 55:5 (2012), 1809–1814.
48. [48] Maguire, J.J., Parker, W.A., Foord, S.M., Bonner, T.I., Neubig, R.R., Davenport, A.P., International union of pharmacology: LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol. Rev. 61:1 (2009), 1–8.
49. [49] Panas, H.N., Lynch, L.J., Vallender, E.J., Xie, Z., Chen, G.L., Lynn, S.K., Scanlan, T.S., Miller, G.M., Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J. Neurosci. Res. 88:9 (2010), 1962–1969.
50. [50] Panas, M.W., Xie, Z., Panas, H.N., Hoener, M.C., Vallender, E.J., Miller, G.M., Trace amine associated receptor 1 signaling in activated lymphocytes. J. Neuroimmune Pharmacol. 7:4 (2012), 866–876.
51. [51] Reese, E.A., Bunzow, J.R., Arttamangkul, S., Sonders, M.S., Grandy, D.K., Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J. Pharmacol. Exp. Ther. 321:1 (2007), 178–186.
52. [52] Sriram, U., Haldar, B., Cenna, J.M., Gofman, L., Potula, R., Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection. Front. Microbiol., 6, 2015, 793.
53. [53] Cisneros, I.E., Ghorpade, A., Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology 85 (2014), 499–507.
54. [54] Bradaia, A., Trube, G., Stalder, H., Norcross, R.D., Ozmen, L., Wettstein, J.G., Pinard, A., Buchy, D., Gassmann, M., Hoener, M.C., Bettler, B., The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. U. S. A. 106:47 (2009), 20081–20086.
55. [55] Leo, D., Mus, L., Espinoza, S., Hoener, M.C., Sotnikova, T.D., Gainetdinov, R.R., Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology 81 (2014), 283–291.
56. [56] Revel, F.G., Moreau, J.L., Gainetdinov, R.R., Bradaia, A., Sotnikova, T.D., Mory, R., Durkin, S., Zbinden, K.G., Norcross, R., Meyer, C.A., Metzler, V., Chaboz, S., Ozmen, L., Trube, G., Pouzet, B., Bettler, B., Caron, M.G., Wettstein, J.G., Hoener, M.C., TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. U. S. A. 108:20 (2011), 8485–8490.
57. [57] Jing, L., Li, J.X., Trace amine-associated receptor 1: a promising target for the treatment of psychostimulant addiction. Eur. J. Pharmacol. 761 (2015), 345–352.
58. [58] Jing, L., Zhang, Y., Li, J.X., Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats. Int. J. Neuropsychopharmacol., 18(4), 2015.
59. [59] Cotter, R., Pei, Y., Mus, L., Harmeier, A., Gainetdinov, R.R., Hoener, M.C., Canales, J.J., The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects. Front. Neurosci., 9, 2015, 39.
60. [60] Sloan, E.K., Capitanio, J.P., Cole, S.W., Stress-induced remodeling of lymphoid innervation. Brain Behav. Immun. 22:1 (2008), 15–21.
61. [61] Straub, R.H., Wiest, R., Strauch, U.G., Harle, P., Scholmerich, J., The role of the sympathetic nervous system in intestinal inflammation. Gut 55:11 (2006), 1640–1649.
62. [62] Johnson, J.D., Campisi, J., Sharkey, C.M., Kennedy, S.L., Nickerson, M., Greenwood, B.N., Fleshner, M., Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135:4 (2005), 1295–1307.
63. [63] Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang, H., Abumrad, N., Eaton, J.W., Tracey, K.J., Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:6785 (2000), 458–462.
64. [64] Martelli, D., McKinley, M.J., McAllen, R.M., The cholinergic anti-inflammatory pathway: a critical review. Auton. Neurosci. 182 (2014), 65–69.
65. [65] Pavlov, O.V., Sel'kov, S.A., Lalayan, D.V., Arzhanova, O.N., Secretion of proinflammatory cytokines by villous chorion tissue in spontaneous abortion. Bull. Exp. Biol. Med. 135:4 (2003), 377–379.
66. [66] Bonaz, B.L., Bernstein, C.N., Brain-gut interactions in inflammatory bowel disease. Gastroenterology 144:1 (2013), 36–49.
67. [67] Matteoli, G., Boeckxstaens, G.E., The vagal innervation of the gut and immune homeostasis. Gut 62:8 (2013), 1214–1222.
68. [68] Matteoli, G., Gomez-Pinilla, P.J., Nemethova, A., Di Giovangiulio, M., Cailotto, C., van Bree, S.H., Michel, K., Tracey, K.J., Schemann, M., Boesmans, W., Vanden Berghe, P., Boeckxstaens, G.E.A., distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut 63:6 (2014), 938–948.
69. [69] Herr, R.D., Caravati, E.M., Acute transient ischemic colitis after oral methamphetamine ingestion. Am. J. Emerg. Med. 9:4 (1991), 406–409.
70. [70] Brannan, T.A., Soundararajan, S., Houghton, B.L., Methamphetamine-associated shock with intestinal infarction. MedGenMed, 6(4), 2004, 6.
71. [71] Carlson, T.L., Plackett, T.P., Gagliano, R.A. Jr., Smith, R.R., Methamphetamine-induced paralytic ileus. Hawaii J. Med. Public Health 71:2 (2012), 44–45.
72. [72] Suzuki, T., Regulation of intestinal epithelial permeability by tight junctions. Cell. Mol. Life Sci. 70:4 (2013), 631–659.
73. [73] Northrop, N.A., Yamamoto, B.K., Methamphetamine effects on blood-brain barrier structure and function. Front. Neurosci., 9, 2015, 69.
74. [74] Lyte, M., Vulchanova, L., Brown, D.R., Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res. 343:1 (2011), 23–32.
75. [75] Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Deng, Y., Blennerhassett, P., Macri, J., McCoy, K.D., Verdu, E.F., Collins, S.M., The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141:2 (2011), 599–609 609. e591-593.
76. [76] Dive, A., Foret, F., Jamart, J., Bulpa, P., Installe, E., Effect of dopamine on gastrointestinal motility during critical illness. Intens. Care Med. 26:7 (2000), 901–907.
77. [77] Dunser, M.W., Hasibeder, W.R., Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J. Intens. Care Med. 24:5 (2009), 293–316.
78. [78] Zizzo, M.G., Mule, F., Mastropaolo, M., Serio, R., D1 receptors play a major role in the dopamine modulation of mouse ileum contractility. Pharmacol. Res. 61:5 (2010), 371–378.
79. [79] Carabotti, M., Scirocco, A., Maselli, M.A., Severi, C., The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 28:2 (2015), 203–209.
80. [80] Fetissov, S.O., Dechelotte, P., The new link between gut-brain axis and neuropsychiatric disorders. Curr. Opin. Clin. Nutr. Metab. Care 14:5 (2011), 477–482.
81. [81] Mayer, E.A., Tillisch, K., Gupta, A., Gut/brain axis and the microbiota. J. Clin. Invest. 125:3 (2015), 926–938.
82. [82] Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., Harris, T.H., Kipnis, J., Structural and functional features of central nervous system lymphatic vessels. Nature 523:7560 (2015), 337–341.
83. [83] Petra, A.I., Panagiotidou, S., Hatziagelaki, E., Stewart, J.M., Conti, P., Theoharides, T.C., Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin. Ther. 37:5 (2015), 984–995.
84. [84] Kerr, D., Krishnan, C., Pucak, M.L., Carmen, J., The immune system and neuropsychiatric diseases. Int. Rev. Psychiatry (Abingdon, England) 17:6 (2005), 443–449.
85. [85] Rusyniak, D.E., Neurologic manifestations of chronic methamphetamine abuse. Psychiatr. Clin. North Am. 36:2 (2013), 261–275.
86. [86] Harms, R., Morsey, B., Boyer, C.W., Fox, H.S., Sarvetnick, N., Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. PLoS One, 7(12), 2012, e49897.
87. [87] Saito, M., Yamaguchi, T., Kawata, T., Ito, H., Kanai, T., Terada, M., Yokosuka, M., Saito, T.R., Effects of methamphetamine on cortisone concentration, NK cell activity and mitogen response of T-lymphocytes in female cynomolgus monkeys. Exp. Anim. 55:5 (2006), 477–481.
88. [88] Peerzada, H., Gandhi, J.A., Guimaraes, A.J., Nosanchuk, J.D., Martinez, L.R., Methamphetamine administration modifies leukocyte proliferation and cytokine production in murine tissues. Immunobiology 218:8 (2013), 1063–1068.
89. [89] Liang, H., Wang, X., Chen, H., Song, L., Ye, L., Wang, S.H., Wang, Y.J., Zhou, L., Ho, W.Z., Methamphetamine enhances HIV infection of macrophages. Am. J. Pathol. 172:6 (2008), 1617–1624.
90. [90] Yu, Q., Zhang, D., Walston, M., Zhang, J., Liu, Y., Watson, R.R., Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int. Immunopharmacol. 2:7 (2002), 951–962.
91. [91] Loftis, J.M., Janowsky, A., Neuroimmune basis of methamphetamine toxicity. Int. Rev. Neurobiol. 118 (2014), 165–197.
92. [92] Shah, A., Silverstein, P.S., Singh, D.P., Kumar, A., Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J. Neuroinflamm., 9, 2012, 52.
93. [93] Najera, J.A., Bustamante, E.A., Bortell, N., Morsey, B., Fox, H.S., Ravasi, T., Marcondes, M.C., Methamphetamine abuse affects gene expression in brain-derived microglia of SIV-infected macaques to enhance inflammation and promote virus targets. BMC. Immunol., 17(1), 2016, 7.
94. [94] Burns, A., Ciborowski, P., Acute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage. Immunobiology 221:2 (2016), 199–207.
95. [95] Talloczy, Z., Martinez, J., Joset, D., Ray, Y., Gacser, A., Toussi, S., Mizushima, N., Nosanchuk, J.D., Goldstein, H., Loike, J., Sulzer, D., Santambrogio, L., Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog., 4(2), 2008, e28.
96. [96] House, R.V., Thomas, P.T., Bhargava, H.N., Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol. Immunotoxicol. 16:1 (1994), 1–21.
97. [97] In, S.W., Son, E.W., Rhee, D.K., Pyo, S., Methamphetamine administration produces immunomodulation in mice. J. Toxicol. Environ. Health A 68:23–24 (2005), 2133–2145.
98. [98] Whitney, N.P., Eidem, T.M., Peng, H., Huang, Y., Zheng, J.C., Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J. Neurochem. 108:6 (2009), 1343–1359.
99. [99] Mahajan, S.D., Hu, Z., Reynolds, J.L., Aalinkeel, R., Schwartz, S.A., Nair, M.P., Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol. Diagn. Ther. 10:4 (2006), 257–269.
100. [100] Golembiowska, K., Konieczny, J., Wolfarth, S., Ossowska, K., Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology 45:4 (2003), 484–492.
101. [101] Shah, A., Silverstein, P.S., Kumar, S., Singh, D.P., Kumar, A., Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. PLoS One, 7(12), 2012, e52060.
102. [102] Zhang, Y., Lv, X., Bai, Y., Zhu, X., Wu, X., Chao, J., Duan, M., Buch, S., Chen, L., Yao, H., Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression. J. Neuroinflamm., 12, 2015, 29.
103. [103] Yang, H., Hreggvidsdottir, H.S., Palmblad, K., Wang, H., Ochani, M., Li, J., Lu, B., Chavan, S., Rosas-Ballina, M., Al-Abed, Y., Akira, S., Bierhaus, A., Erlandsson-Harris, H., Andersson, U., Tracey, K.J., A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:26 (2010), 11942–11947.
104. [104] Bustin, M., Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19:8 (1999), 5237–5246.
105. [105] Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R., Tsung, A., HMGB1: endogenous danger signaling. Mol. Med. 14:7–8 (2008), 476–484.
106. [106] Quinton, M.S., Yamamoto, B.K., Neurotoxic effects of chronic restraint stress in the striatum of methamphetamine-exposed rats. Psychopharmacology (Berl.) 193:3 (2007), 341–350.
107. [107] Raudensky, J., Yamamoto, B.K., Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function. Brain Res. 1135:1 (2007), 129–135.
108. [108] Cadet, J.L., Jayanthi, S., Deng, X., Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17:13 (2003), 1775–1788.
109. [109] Guilarte, T.R., Nihei, M.K., McGlothan, J.L., Howard, A.S., Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122:2 (2003), 499–513.
110. [110] Lin, Y.-M., Sung, W.-W., Hsieh, M.-J., Tsai, S.-C., Lai, H.-W., Yang, S.-M., Shen, K.-H., Chen, M.-K., Lee, H., Yeh, K.-T., Chen, C.-J., High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One, 10(11), 2015, e0142656.
111. [111] Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., Uike, N., Nagafuji, K., Okamura, T., Akashi, K., Takayanagi, R., Shiratsuchi, M., Ohshima, K., Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:19 (2015), 2193–2201.
112. [112] He, J., Hu, Y., Hu, M., Li, B., Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci. Rep., 5, 2015, 13110.
113. [113] Mishra, V., Schuetz, H., Haorah, J., Differential induction of PD-1/PD-L1 in neuroimmune cells by drug of abuse. Int. J. Physiol. Pathophysiol. Pharmacol. 7:2 (2015), 87–97.
114. [114] Sheppard, K.A., Fitz, L.J., Lee, J.M., Benander, C., George, J.A., Wooters, J., Qiu, Y., Jussif, J.M., Carter, L.L., Wood, C.R., Chaudhary, D., PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574:1–3 (2004), 37–41.